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Abstract
Background: Stereotactic body radiation therapy (SBRT) administered via a helical tomotherapy (HT) system is an
effective modality for treating lung cancer and metastatic liver tumors. Whether SBRT delivered via HT is a feasible
alternative to brachytherapy in treatment of locally advanced cervical cancer in patients with unusual anatomic
configurations of the uterus has never been studied.
Case Presentation: A 46-year-old woman presented with an 8-month history of abnormal vaginal bleeding. Biopsy
revealed squamous cell carcinoma of the cervix. Magnetic resonance imaging (MRI) showed a cervical tumor with
direct invasion of the right parametrium, bilateral hydronephrosis, and multiple uterine myomas. International
Federation of Gynecology and Obstetrics (FIGO) stage IIIB cervical cancer was diagnosed. Concurrent
chemoradiation therapy (CCRT) followed by SBRT delivered via HT was administered instead of brachytherapy
because of the presence of multiple uterine myomas with bleeding tendency. Total abdominal hysterectomy was
performed after 6 weeks of treatment because of the presence of multiple uterine myomas. Neither pelvic MRI nor
results of histopathologic examination at X-month follow-up showed evidence of tumor recurrence. Only grade 1
nausea and vomiting during treatment were noted. Lower gastrointestinal bleeding was noted at 14-month follow-
up. No fistula formation and no evidence of haematological, gastrointestinal or genitourinary toxicities were noted
on the most recent follow-up.
Conclusions: CCRT followed by SBRT appears to be an effective and safe modality for treatment of cervical cancer.
Larger-scale studies are warranted.
Background
It has been demonstrated that concurrent chemoradia-
tion therapy (CCRT) followed by intracavity radiation is
effective in the treatment of advanced cervical cancer
[1]. Although external beam radiotherapy combined
with brachytherapy is associated with high survival rates
and low complication rates [2,3], patients with contrain-
dications to brachytherapy, namely patients with unu-
sual anatomic configurations of the pelvis or tumors,
may benefit from higher doses of external beam irradia-
tion [2]. However, studies have shown that external
beam irradiation used throughout the treatment course
for cervical cancer is associated with poor survival, poor
local control, and a high incidence of side effects [3,4].
Molla et al. found that the use of intensity-modulated
radiation therapy (IMRT) to deliver a final boost to areas
at high risk for relapse in patients with endometrial or
cervical cancer was feasible, well tolerated, and may be
considered an acceptable alternative tobrachytherapy [5].
Helical tomotherapy (HT), an image-guided IMRT, can
deliver highly conformal dose distributions and provides
an impressive critical organ sparing ability for cervical
cancer [6]. Studies have shown that stereotactic body
radiation therapy (SBRT), when using image-guided
IMRT capable of delivering high doses of radiation in
hypo-fractions, such as the HT system, is an effective and
well-tolerated treatment for local control of tumors
metastatic to the liver and lung [7,8]. Herein, we report
on a patient with locally advanced cervical cancer that
was treated with HT-guided SBRT rather than bra-
chytherapy because the presence of an unusual anatomic
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use of brachytherapy.
Case presentation
A 46-year-old woman presented with an 8-month his-
tory of abnormal vaginal bleeding. Cervical biopsy and
Papanicolaou test results showed squamous cell carci-
noma of the cervix (Figure 1). Magnetic resonance ima-
ging (MRI) showed a cervical tumor with direct invasion
of the right parametrium, multiple uterine myomas, and
bilateral hydronephrosis (Figure 2). Laboratory test
results revealed a BUN level of 21 mg/dL and a Creati-
nine level of 0.7 mg/dL. International Federation of
Gynecology and Obstetrics (FIGO) stage IIIB cervical
cancer was diagnosed. There was no evidence of distant
metastasis at that time. The patient underwent CCRT.
The major tumor and whole pelvis was treated with 54
and 48.5 Gy in 27 fractions over 6 weeks with simulta-
neous integrated boost techniques. The Pinnacle3 treat-
ment planning system with 6- MV linear accelerator
(Philips Healthcare, Madison, Wisconsin, USA) was used
for treatment. Weekly cisplatin at a dose of 40 mg/m
2 was
administered during external radiation for 5 weeks con-
current with radiotherapy. Because of the presence of mul-
tiple uterine myomas with bleeding tendency, the SBRT
technique with 24 Gy delivered to primary tumor part
with 0.7 cm margin as PTV in 6 fractions over one week
was used in place of brachytherapy after receiving approval
from the institutional ethics committee of the Far Eastern
Memorial Hospital. The field width, pitch, and modulation
factor (MF) used to optimize SBRT treatment were 2.5
cm, 0.32, and 3.0, respectively. Moreover, the 90% isodose
surface covered between 95% and 98% of the planning
target volume (PTV). Volumes of overdose exceeding
115% < 5% of the PTV were considered acceptable. Fol-
low-up MRI taken one month after completion of treat-
ment showed no evidence of tumor recurrence (Figure 3).
Figure 1 Photomicrograph of cervical biopsy specimen before
treatment shows nests of moderately differentiated squamous
carcinoma cells invading deeply into the fibrous stroma (H-E
200X). The arrows indicate the tumor nests.
Figure 2 MR image of the pelvis before treatment shows direct
invasion of the cervical tumor into the right parametrium,
bilateral hydronephrosis, and multiple uterine myomas. The
solid arrows indicate the parametrium invasion, the uterine myomas,
the tumor, and the uterine cavity. The dotted arrow indicates
adenomyosis.
Figure 3 Pelvic MRI after concurrent chemoradiation therapy
and HT-guided SBRT shows multiple uterine myomas and
adenomyosis without local recurrence or pelvic
lymphadenopathy.
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several days of continuous vaginal bleeding accompanied
by abdominal pain. The etiology of the bleeding and
abdominal discomfort was believed to be due to the multi-
ple uterine myomas. Therefore, a total abdominal hyster-
ectomy was performed. Histopathologic examination
revealed chronic inflammation of the cervix with no resi-
dual tumor (Figure 4). Toxicity of treatment was scored
according to the Common Terminology Criteria for
Adverse Events v3.0 (CTCAE v3.0). Only grade 1 nausea
and vomiting during treatment were noted. At 14-month
follow-up, controllable ulceration and mucositis were
noted in the rectal area. (Figure 5) At the 22-month fol-
low-up, no haematological, gastrointestinal, or genitourin-
ary toxicities were noted. In addition, there was no
evidence of fistula formation, local recurrence, or distant
metastasis.
Conclusions
External-beam irradiation could be an alternative to bra-
chytherapy in cervical cancer patients with contraindica-
tions to external irradiation and brachytherapy [2].
IMRT and 3-dimensional conformal radiotherapy
(3DCRT) are now widely used radiotherapy techniques
for various cancers and have been shown to be accepta-
ble alternatives to brachytherapy for the treatment of
gynecologic malignancies [5,9].
HT-guided SBRT has been shown to be effective and
well tolerated in patients with metastatic liver tumors
[7], and in patients with small lung tumors [8]. In our
patient, image-guided SBRT administered as a boost fol-
lowing CCRT resulted in a recurrence-free outcome
without fistula formation at 22-month follow-up (Figure
3a n d4 ) .H o w e v e r ,a t1 4 - m o n t hf o l l o w - u p ,t h ep a t i e n t
presented with lower GI bleeding (Figure 5). Retrospect-
ing the planning, the conformal index [10] is 1.24. Addi-
tionally, the dose distribution has described in Figure 6.
The mean dose of rectum is 45.5 Gy and the maximum
dose of the rectum is 81 Gy where is close to the tumor
and compatible to the bleeding area. The incidence of
major late sequalae of RT for stages IIB and III of the
cervix ranges from 10% to 15% [11]. Perez et al. [11]
and Pourquier et al. [12] reported that with doses below
75 to 80 Gy delivered in limited volumes by a combina-
tion of external beam and intracavitary insertions with
low dose rate (60 to 80 rad/hr), the incidence of grade 2
and 3 complications was less than 5%. However, with
higher doses, the incidence of complications increased
to 10% to 15%. In patients receiving total doses of 60
Gy to the rectum, more complications were noted [11].
Lower GI bleeding as a late complication of an external
beam boost has been reported [2,5]. Although HT has
t h ea b i l i t yt oa c c u r a t e l yi d e n t i f yb o t ht h ee x a c ts h a p e
and location of the tumor so as to distribute the dose as
close as possible to the margin around the target, the
radiation oncologist needs to monitor the maximum
d o s e st oo r g a n sa tr i s k( O A R s )a r o u n dt h et u m o ri n
order to minimize, if not avoid, complications.
Uterine myomas are the most common neoplasms of
the female pelvis, occurring in 20 - 25% of women of
reproductive age [13] and the common symptoms were
menorrhagia or metrorrhagia, or both [14-16]. It is the
existence and level of bother of uterine fibroid symptoms
that lead women to seek treatment, with the current
standard of care being abdominal hysterectomy [17,18].
Symptoms of chronic radiation proctitis can manifest
as mucous rectal discharge, diarrhea, urgency, pain,
bleeding, and anemia. Radiation proctitis can be treated
Figure 4 Photomicrograph of cervical biopsy specimen taken
after concurrent chemoradiation therapy followed by HT-
guided SBRT shows only scattered nests of mononuclear
inflammatory cells (H-E 200X).
Figure 5 At 14-month follow-up, ulceration and mucositis in
the rectal area were noted. The arrows indicate the ulceration
and mucositis in the rectal area.
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sucralfate enemas in combination with [21] or without
[22] sulfasalazine, formalin [23,24], endoscopic Nd:YAG
laser treatment [25,26], electrocoagulation, argon plasma
coagulation [27,28], or hyperbaric oxygen [29,30]. How-
ever, the effectiveness of many of those therapeutic
modalities has not been proven in controlled trials.
HT-guided SBRT appears to be an effective and safe
alternative to brachytherapy for treatment of cervical
cancer in patients with contraindications to that conven-
tional treatment modality. Long-term follow-up is
needed to confirm these preliminary findings. Radiation
oncologists need to monitor the maximum doses to
organs at risk around the tumor in order to avoid
SBRT-induced complications.
Consent
Written informed consent was obtained from the patient
for publication of this case report and all accompanying
images. A copy of the written consent is available
for review.
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